Co-Authors
This is a "connection" page, showing publications co-authored by SAMIR HANASH and ANIRBAN MAITRA.
Connection Strength
1.876
-
Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Gastroenterology. 2021 03; 160(4):1373-1383.e6.
Score: 0.189
-
CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. JCO Precis Oncol. 2020 Nov; 4:426-436.
Score: 0.188
-
A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. J Natl Cancer Inst. 2019 04 01; 111(4):372-379.
Score: 0.168
-
Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Nat Commun. 2019 01 16; 10(1):254.
Score: 0.166
-
Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. J Natl Cancer Inst. 2017 04 01; 109(4).
Score: 0.146
-
Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer. PLoS One. 2016; 11(3):e0152300.
Score: 0.136
-
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. J Natl Cancer Inst. 2015 Aug; 107(8).
Score: 0.129
-
A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone. Cancer Lett. 2024 Nov 01; 604:217245.
Score: 0.061
-
Therapeutic targeting of Syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. bioRxiv. 2024 Aug 08.
Score: 0.061
-
A Rigorous Multi-Laboratory Study of Known PDAC Biomarkers Identifies Increased Sensitivity and Specificity Over CA19-9 Alone. bioRxiv. 2024 May 26.
Score: 0.060
-
Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Gut. 2024 03 07; 73(4):639-648.
Score: 0.059
-
Contributions of the Microbiome-Derived Metabolome for Risk Assessment and Prognostication of Pancreatic Cancer. Clin Chem. 2024 01 04; 70(1):102-115.
Score: 0.058
-
A blood-based metabolomic signature predictive of risk for pancreatic cancer. Cell Rep Med. 2023 09 19; 4(9):101194.
Score: 0.057
-
Integrated spatial transcriptomics and lipidomics of precursor lesions of pancreatic cancer identifies enrichment of long chain sulfatide biosynthesis as an early metabolic alteration. bioRxiv. 2023 Aug 15.
Score: 0.057
-
CES2 sustains HNF4a expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. Mol Metab. 2022 02; 56:101426.
Score: 0.051
-
Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN. Cancer Epidemiol Biomarkers Prev. 2020 12; 29(12):2513-2523.
Score: 0.046
-
Plasma-Derived Extracellular Vesicles Convey Protein Signatures that Reflect Pathophysiology in Lung and Pancreatic Adenocarcinomas. Cancers (Basel). 2020 May 02; 12(5).
Score: 0.045
-
Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019 08 08; 178(4):795-806.e12.
Score: 0.043
-
Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature. 2019 04; 568(7752):410-414.
Score: 0.042
-
Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. Ann Oncol. 2018 01 01; 29(1):223-229.
Score: 0.039
-
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci U S A. 2017 09 19; 114(38):10202-10207.
Score: 0.038
-
High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann Oncol. 2017 04 01; 28(4):741-747.
Score: 0.037